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Case-control studywell-characterized genetic risk factor for late-onset Alzheimer disease (LOAD).
Nevertheless, using high-density single nucleotide polymorphisms (SNPs), there have only been a few
studies involving genetic association and linkage disequilibrium (LD) analyses of in and around the APOE.
Here, we report ﬁne mapping of a genomic region (about 200 kb) including the APOE in Japanese using 260
SNPs (mean intermaker distance, 0.77 kb). A case-control study demonstrated that 36 of these SNPs
exhibited signiﬁcance after adjustment for multiple testing. These SNPs are located in a genomic region
including four genes, PVRL2, TOMM40, APOE and APOC1. Recombination rate estimation revealed that the
associated region is ﬁrmly sandwiched between two recombination hotspots. Strong LD between these SNPs
was observed (mean |D′|=0.914). These data suggest that the three genes other than APOE, i.e. PVRL2,
TOMM40 and APOC1, could also yield a predisposition to LOAD.
© 2009 Elsevier Inc. All rights reserved.IntroductionAlzheimer disease (AD) is the main cause of dementia in the
elderly. Its main neuropathological features are extracellular
deposition of amyloid β-protein (Aβ) and intracellular formation
of neuroﬁbrillary tangles. Late-onset AD (LOAD), accounting for
∼95% of AD, is thought to be a multi-factorial disease, probablyNiigata 951-8585, Japan. Fax:
o).
ll rights reserved.caused by complicated interactions between genetic and environ-
mental factors.
To date, only the apolipoprotein E gene (APOE) on chromosome
19q is universally recognized as a major disease susceptibility gene for
LOAD [1–3]. APOE has three common alleles, APOE-ɛ2, APOE-ɛ3 and
APOE-ɛ4. These three alleles are deﬁned by two non-synonymous
single nucleotide polymorphisms (SNPs), rs429358 (TGC→CGC,
Cys112Arg) and rs7412 (CGC→TGC, Arg158Cys): APOE-ɛ2, T-T (Cys-
Cys); APOE-ɛ3, T-C (Cys-Arg); and APOE-ɛ4, C-C (Arg-Arg). Among
these alleles, the APOE-ɛ3 one is the most frequent (0.49–0.91), the
APOE-ɛ2 one being the rarest (0.0–0.15), in all populations thus far
investigated [4]. We previously reported that in Japanese normal
controls (≥60 y.o.) the frequencies of the APOE-ɛ2, APOE-ɛ3 and
Table 1
Subject information
LOAD Control
No. of subjects 547 715
Frequency of female 0.717 0.544
AAO/AAE (mean±SD) 73.0±6.9 73.0±6.8
APOE genotype
2⁎2 0 4
2⁎3 19 57
2⁎4 6 7
3⁎3 279 529
3⁎4 196 117
4⁎4 47 1
APOE-ɛ4 allele frequency 0.269 0.087
442 N. Takei et al. / Genomics 93 (2009) 441–448APOE-ɛ4 alleles are 0.05, 0.86 and 0.09, respectively [5,6]. Compared to
the APOE-ɛ3 allele, the APOE-ɛ4 allele is a strong risk factor with an
odds ratio (OR) of 2.0–4.0, the APOE-ɛ2 allele being protective as to
LOAD [7,8].
Recent genome-wide association studies (GWAS) reconﬁrmed that
an APOE linkage disequilibrium (LD) locus is strongly associated with
LOAD [9–11]. Through these GWAS, it appears to be ﬁnally demon-
strated that reproducible, strong association signals are only observed
in and around the APOE. Up to now, it has been implicitly assumed
that the genetic association in and around the APOE in LOAD
thoroughly reﬂects the APOE-ɛ4 association itself, owing to strongFig. 1. Genomic region associated with LOAD. (A) Plot of − log10 Punadj-allele-values of 171 SN
dotted line indicates the signiﬁcant threshold of the Punadj-allele-value=0.0003 (Bonferro
labeled. (B) Recombination hotspots, HS1 and HS2. Genomic positions are according to NCBLD with the two APOE SNPs rs429358 and rs7412 [11]. However, it was
recently suggested that multiple (cis-regulatory) SNPs in and around
the APOE may contribute to disease susceptibility via alteration of
gene expression. Belbin et al. [12] found that the rate of the cognitive
decline in AD patients is affected by a SNP (rs440446) lying in a
regulatory element of intron 1 of the APOE. Interestingly, the effect of
this SNP on the cognitive decline seems to be independent of the
APOE-ɛ4 allele. Quantitative trait analysis also indicated that three
cis-acting SNPs (rs449647, rs17684509 and rs7247551) of the APOE
and three SNPs (rs11556505, n17664883 and rs157584) within the
translocase of the outer mitochondrial membrane 40 homolog (yeast)
gene (TOMM40), proximally located upstream of the APOE, are
associated with the level of cerebrospinal ﬂuid APOE in healthy non-
demented subjects [13]. These data raise the possibility that other
SNPs which affect a variety of quantitative traits involved in the LOAD
pathogenesis might be hidden in and around the APOE. Therefore, it
would be very important to conduct a genetic association study using
a sufﬁcient number of SNPs to entirely survey the genomic region
comprising the APOE.
Here, we carried out a high-density SNP-based case-control
association study (N=1262 [LOAD, 547; control, 715]) using 260
SNPs for an approximately 200 kb genomic region comprising 8 genes
in addition to the APOE: the Cas-Br-M (murine) ecotropic retroviral
transforming sequence c gene (CBLC), the basal cell adhesion
molecule (Lutheran blood group) gene (BCAM), the poliovirus
receptor-related 2 (herpesvirus entry mediator B) gene (PVRL2),Ps. Horizontal arrows indicate the transcriptional orientations of individual genes. The
ni correction). The most signiﬁcant SNP, rs429358 (Punadj-allele-value=4.32E−34), is
I build 36.
443N. Takei et al. / Genomics 93 (2009) 441–448TOMM40, the apolipoprotein C-I gene (APOC1), the apolipoprotein C-
IV gene (APOC4), the apolipoprotein C-II gene (APOC2), and the cleft
lip and palate associated transmembrane protein 1 gene (CLPTM1).
Fine LD mapping and estimation of recombination hotspots were also
performed to clarify the genetic structure in this region.
Results
Distribution of APOE genotypes
We determined the APOE genotypes of all subjects (N=1262)
enrolled in this study, bymeans of TaqMan® allelic discrimination and
direct cycle sequencing for the two non-synonymous SNPs rs429358
and rs7412. Perfect concordance in the genotyping was obtained
between the two methods. Deviation from the Hardy–Weinberg
equilibrium (HWE) was assessed in controls (N=715). The HWE
P-values of SNPs rs429358 and rs7412 were 0.0358 and 0.1934,
respectively. The genotypic distribution of the APOE is presented in
Table 1. We compared the allelic distribution of the APOE using a 2×3
contingency table between LOAD patients (ɛ2, 25; ɛ3, 773; ɛ4, 296)
and controls (ɛ2, 72; ɛ3, 1232; ɛ4, 126). As expected, a signiﬁcant
difference was observed: degree of freedom [df]=2, chi-square
value=152.34, P-value=3.06E−34. We further computed an esti-
mate of the relative risk for LOAD using a 2×2 contingency table.
Compared to the APOE-ɛ3 allele, the APOE-ɛ4 one exhibited a strongTable 2
Case-control study of the 36 signiﬁcant SNPs
SNP ID Position(bp)a Alleleb MAFc GSRd Number of genotypes
LOAD Control
MM Mm mm MM
rs419010 50060160 A/g 0.493 98.6 112 278 150 206
rs394221 50060264 C/t 0.487 92.5 149 269 91 153
rs4803766 50063008 G/a 0.434 98.2 136 273 130 265
rs395908 50065579 G/a 0.280 98.2 228 240 70 414
rs519113 50069307 C/g 0.273 98.3 237 226 73 423
rs412776 50071356 G/a 0.257 97.9 245 230 65 440
rs3865427 50072801 C/a 0.209 98.3 299 198 43 481
rs3852860 50074806 T/c 0.321 96.9 191 268 77 359
rs3852861 50074901 T/g 0.318 98.7 196 261 80 375
rs6857 50084094 C/t 0.180 97.0 316 184 26 504
19AyD0326 50086176 T/c 0.194 99.3 292 212 40 524
rs157580 50087106 A/g 0.467 98.2 192 262 85 162
rs157581 50087554 T/c 0.329 97.1 194 251 90 363
rs157582 50088059 C/t 0.292 97.9 212 240 80 417
rs157583 50088513 G/t 0.043 96.8 465 57 7 659
rs1160983 50089069 G/a 0.048 98.4 511 30 0 616
rs157587 50090046 A/g 0.043 97.5 467 58 6 668
rs283817 50092615 T/g 0.044 98.6 468 61 7 673
rs573199 50094959 C/t 0.038 97.8 472 52 7 675
rs1160985 50095252 C/t 0.266 98.7 323 192 28 346
rs760136 50095698 A/g 0.265 97.5 323 191 27 338
rs741780 50096271 T/c 0.269 97.9 314 193 26 340
rs394819 50096419 G/t 0.043 98.7 473 58 7 672
rs405697 50096531 G/a 0.496 98.4 98 276 167 216
rs10119 50098513 C/t 0.229 99.1 249 225 66 509
rs446037 50099277 G/t 0.044 98.6 468 60 7 674
rs434132 50099560 C/g 0.043 99.0 474 59 7 675
rs7259620 50099628 G/a 0.264 98.3 319 189 27 349
rs449647 50100404 A/t 0.049 97.6 457 70 2 658
rs769446 50100468 T/c 0.036 99.4 522 22 0 647
rs440446 50101007 C/g 0.426 93.9 125 270 129 261
rs429358 50103781 T/c 0.167 100.0 298 202 47 590
rs7256200 50107775 G/t 0.128 98.9 348 164 27 608
rs483082 50108018 G/t 0.208 97.1 274 213 51 504
rs584007 50108318 G/a 0.439 98.2 129 279 130 248
rs4420638 50114786 A/g 0.203 98.1 297 199 41 565
M and m represent major and minor alleles, respectively. The MAF and GSR values were ca
a Genomic positions are according to NCBI build 36.
b Major and minor alleles are indicated in upper and lower case letters, respectively.
c MAF, minor allele frequency.
d GSR, genotyping success rate.risk effect for LOAD (df=1, chi-square value=141.15, P-value=1.49E
−32; OR=3.74, 95% conﬁdence intervals [CIs]=2.98–4.20) and the
APOE-ɛ2 one was protective (df=1, chi-square value=6.42, P-
value=1.13E−2; OR=0.55, 95% CIs=0.35–0.70), which are consis-
tent with results of many preceding genetic studies on AD [8; ALZgene
web site, http://www.alzforum.org/res/com/gen/alzgene/].
Allelic association study on in and around the APOE
We conducted high-density SNP genotyping in and around the
APOE to identify novel SNPs associated with LOAD in Japanese. Two
hundred and ﬁfty-seven SNPs (Supplementary Table 1), spanning
about 200 kb (49.988–50.188 Mb), were selected from a genomic
region including the nine genes (Fig. 1A) mentioned under Introduc-
tion. They were genotyped using a sample set, All, comprising 1262
subjects (LOAD, 547; control, 715). Among them, 171 SNPs were
actually polymorphic with minor allele frequency (MAF)≥0.01 and
did not show signiﬁcant deviation from the HWE (P-value≥0.01) in
the Japanese population: 8 missense mutations, 5 silent mutations, 1
in the 5′ UTR and 4 in the 3′ UTR, 108 in introns, and 45 in intergenic
regions (Supplementary Table 1). The mean inter-marker distance±
standard deviation (SD) was 1.18±1.79 kb (95% CIs, 0.91–1.45; range,
7–13,801 bp).
For these 171 SNPs, an allelic contingency table (2×2)-based chi-
squared test was performed using the All sample set to identify SNPsNumber of alleles Allelic P-value OR 95% CIs
LOAD Control
Mm mm M m M m
348 150 502 578 760 648 2.10E−04 1.35 (1.15–1.58)
325 180 567 451 631 685 2.04E−04 0.73 (0.62–0.86)
328 107 545 533 858 542 9.16E−08 1.55 (1.32–1.82)
261 26 696 380 1089 313 9.24E−13 1.90 (1.59–2.27)
258 23 700 372 1104 304 3.77E−13 1.93 (1.61–2.31)
237 19 720 360 1117 275 1.81E−14 2.03 (1.69–2.44)
206 14 796 284 1168 234 5.27E−09 1.78 (1.47–2.16)
292 36 650 422 1010 364 1.34E−11 1.80 (1.52–2.14)
294 39 653 421 1044 372 6.99E−12 1.81 (1.53–2.15)
183 11 816 236 1191 205 7.88E−07 1.68 (1.37–2.07)
176 9 796 292 1224 194 1.50E−16 2.31 (1.89–2.83)
351 187 646 432 675 725 6.91E−09 0.62 (0.53–0.73)
281 47 639 431 1007 375 6.31E−12 1.81 (1.53–2.15)
250 36 664 400 1084 322 1.87E−15 2.03 (1.70–2.42)
34 0 987 71 1352 34 2.70E−07 2.86 (1.89–4.34)
82 3 1052 30 1314 88 4.68E−05 0.43 (0.28–0.65)
36 0 984 70 1372 36 7.79E−07 2.71 (1.80–4.09)
35 0 997 75 1381 35 5.43E−08 2.97 (1.97–4.47)
28 0 996 66 1378 28 5.73E−08 3.26 (2.08–5.11)
300 57 838 248 986 414 2.12E−04 0.70 (0.59–0.85)
294 57 837 245 970 408 1.03E−04 0.70 (0.58–0.84)
306 57 821 245 986 420 1.31E−04 0.70 (0.58–0.84)
35 0 1004 72 1379 35 2.76E−07 2.83 (1.87–4.27)
348 137 472 610 780 622 2.90E−09 1.62 (1.38–1.90)
189 13 723 357 1207 215 3.62E−26 2.77 (2.29–3.36)
34 1 996 74 1382 36 1.45E−07 2.85 (1.90–4.28)
34 0 1007 73 1384 34 9.64E−08 2.95 (1.95–4.47)
301 56 827 243 999 413 2.54E−04 0.71 (0.59–0.85)
44 1 984 74 1360 46 2.14E−05 2.22 (1.53–3.24)
60 4 1066 22 1354 68 2.28E−04 0.41 (0.25–0.67)
319 81 520 528 841 481 7.67E−12 1.78 (1.51–2.09)
124 1 798 296 1304 126 4.32E−34 3.84 (3.06–4.81)
101 0 860 218 1317 101 2.74E−22 3.31 (2.57–4.25)
172 12 761 315 1180 196 9.58E−20 2.49 (2.04–3.04)
358 95 537 539 854 548 4.44E−08 1.56 (1.33–1.84)
135 1 793 281 1265 137 3.78E−27 3.27 (2.62–4.09)
lculated for the sample set All.
444 N. Takei et al. / Genomics 93 (2009) 441–448associatedwith LOAD. Thirty-ﬁve of these SNPs exhibited signiﬁcance:
range of unadjusted allelic P-values (Punadj-allele-value), 4.32E−34–
2.00E−4 (Table 2 and Fig. 1A). These SNPs remained signiﬁcant even
after Bonferroni correction for multiple testing (Fig. 1A). The genomic
positions of the SNPs, spanning approximately 52.3 kb, are presented
in Fig. 1 and Table 2. It was found that the associated region
encompasses three additional genes to the APOE, i.e. PVRL2,
TOMM40 and APOC1 (Fig. 1).
The 171 SNPs were further examined by stratiﬁed analysis, based
on the APOE genotypes, using the chi-squared test. Three sub-sample
sets, Positive-ɛ4 (LOAD, 247; control, 123), Negative- ɛ4 (LOAD, 296;
control, 586), and ɛ3⁎3 (LOAD, 277; control, 525), were used. We did
not observe any signiﬁcant allelic association of these SNPs with LOAD
in any sub-sample set (Supplementary Fig. 1).
Novel variants in and around PVRL2 and TOMM40
Among the four associated genes mentioned above, APOE and
APOC1 have been genetically well investigated as disease suscept-
ibility genes for LOAD [8; ALZgene web site, http://www.alzforum.
org/res/com/gen/alzgene/]. On the other hand, the genetic andFig. 2. LDmapping. (A) Horizontal arrows indicate the transcriptional orientations of individu
SNPs are indicated by long vertical lines. |D′| and r-square are indicated in (B) and (C), respbiological relationships of the two remaining genes, PVRL2 and
TOMM40, to LOAD have not been well evaluated so far. For these
two genes, it is meaningful to explore novel DNA variants that could
affect gene function and transcription. To achieve this purpose, we
sequenced a total of 19 exons (PVRL2, 10 exons; and TOMM40, 9
exons), their exon–intron boundaries and an about 200 bp 5′ region
upstream of these genes. Two non-synonymous variants were
identiﬁed in exons 2 (GenBank accession number, NM_001042724:
c.349GNA, p.Glu101Lys; designated as 19AyD0324) and 7 (GenBank
accession number, NM_001042724:c.1111GNA, p.Ala355Thr; desig-
nated as 19AyD0325) within PVRL2 (Supplementary Table 2). For
TOMM40, there was one variant 337 bp upstream from the translation
initiation site (GenBank accession number, NC_00019.8:g.-337TNC;
designated as 19AyD0326) (Supplementary Table 2). A search of the
UCSC genomic database (http://genome.ucsc.edu/) demonstrated
that all three variants are novel.
The variants, i.e. 19AyD0324, 19AyD0325 and 19AyD0326, were
genotyped by means of the TaqMan® method using the overall
sample set All. The minor alleles for the two variants 19AyD0324
(nucleotide A) and 19AyD0325 (nucleotide A) both exhibited very
low frequencies: 19AyD0324, 0.00821 in LOAD and 0.0141 inal genes. Vertical lines indicate the 171 SNPs, described under Results. The 35 signiﬁcant
ectively. The thick vertical lines in (B) and (C) indicate the signiﬁcant SNPs.
445N. Takei et al. / Genomics 93 (2009) 441–448controls; and 19AyD0325, 0.0009 in LOAD and 0.0007 in controls. No
allelic association with LOAD was exhibited by these two variants:
Punadj-allele-values of 0.172 for 19AyD0324 and 0.853 for 19AyD0325.
However, the variant 19AyD0326 was highly polymorphic with MAF
of 0.268 for LOAD and 0.137 for controls, and was signiﬁcantly
associated with LOAD (Punadj-allele-value, 1.50E−16; OR [95% CIs], 2.31
[1.89–2.86]) (Table 2).Fig. 3. LD maps for the signiﬁcant 36 SNPs plus the APOE SNP rs7412. |D′| was computed usi
The two APOE SNPs, rs429358 and rs7412, are enclosed by rectangles.LD patterns and recombination hotspots
Fine-scale LD maps in and around the APOE were constructed
using LOAD (N=547) and control subjects (N=715) to further
characterize the signiﬁcant SNPs (Table 2). We ﬁrst surveyed LD
patterns across the 200-kb genomic region in and around the APOE.
For this analysis, 172 SNPs, including the SNP 19AyD0326, withng LOAD (A, N=547), control (B, N=715), and LOAD+Control (C, N=1262) subjects.
446 N. Takei et al. / Genomics 93 (2009) 441–448MAF≥0.01, were used. The mean inter-marker distance±SD was 1.17
± 1.78 kb (95% CIs, 0.9–1.44; range, 7–13,801 bp). We observed a
highly structured single LD block spanning about 48.49 kb down-
stream of the APOC1, which encompassed three genes, i.e. APOC4,
APOC2 and CLPTM1 (Fig. 2B and Supplementary Fig. 2). A solid LD
pattern was not detected for the BCAM-APOC1 region extending
roughly for 117.5 kb, suggesting the possibility that recombination has
frequently occurred in this region during human evolution.
In order to determine whether or not there are recombination
hotspots in and around the APOE, we estimated the recombination
rates. Twomajor recombination hotspots were identiﬁed in intron 1 of
PVRL2 (HS1), and an intergenic region between APOC1 and APOC4
(HS2) (Fig. 1B). There were no remarkably differences in the positions
of these hotspots between LOAD and control subjects (data not
shown). All 36 signiﬁcant SNPs (Table 2)were found to be sandwiched
between HS 1 and HS2, spanning approximately 54.6 kb (Fig. 1B). No
deﬁnite recombination hotspots were detected in the solid LD region
extending from APOC4 to CLPTM1 (Figs. 1B and 2B).
We carried out LD analysis using only the signiﬁcant 36 SNPs.
These SNPs were in a relatively strong LD region in both LOAD (Fig.
3A) and control subjects (Fig. 3B). In particular, the LD between the
most signiﬁcant APOE SNP, rs429358, and the remaining 35 SNPs was
very strong. The mean values of |D′| and r2 were 0.91 (SD, 0.13; 95%
CIs, 0.87–0.95; range, 0.53–1.00) and 0.32 (SD, 0.22; 95% CIs, 0.25–
0.40; range, 0.01–0.88) in LOAD subjects, and 0.91 (SD, 0.14; 95% CIs,
0.87–0.96; range, 0.44–1.00) and 0.22 (SD, 0.18; 95% CIs, 0.16–0.28;
range, 0.01–0.83) in controls, respectively.
Case-control haplotype analysis
Since combinations of multiple SNPs might increase the LOAD risk,
we conducted case-control haplotype analysis, using the 36 signiﬁcant
SNPs plus the APOE SNP rs7412 with the sample set All. Among the 18
haplotypes estimated, three carrying the APOE-ɛ4 allele (H3, H7 and
H12) exhibited signiﬁcance and caused an increased risk for LOAD
(Table 3). Haplotype H14 involving the APOE-ɛ2 allele showed a
protective effect as to LOAD. We did not observe a more signiﬁcant
haplotype than APOE SNP rs429358 (Punadj-allele-value=4.32E−34)
(Tables 2 and 3).Table 3
Case-control haplotype analysis of the 36 signiﬁcant SNPs plus APOE SNP rs7412
ID Haplotypea APOE Frequencies
All LOAD
H1 ACGGCGCTTCTgTCGGATCCATGaCGCGATCTCGGaA ɛ3 0.291 0.275
H2 gtaGCGCTTCTATCGGATCtgcGGCGCaATgTCGGGA ɛ3 0.073 0.073
H3 gtaagaacgtCActGGATCCATGGtGCGATgcCttGg ɛ4 0.069 0.113
H4 gtGGCGCTTCTgTCGGATCCATGaCGCGATCTCGGaA ɛ3 0.043 0.035
H5 gtaGCGCTTCTgTCGGATCCATGaCGCGATCTCGGaA ɛ3 0.038 0.038
H6 ACGGCGCTTCTgcCGGATCCATGaCGCGATCTCGGaA ɛ3 0.032 0.030
H7 gtaagaCcgCTActtGggtCATtGttgGtTgcCGtGg ɛ4 0.031 0.054
H8 gtaagaacgtCActGGATCCATGGtGCGATCTCGGaA ɛ3 0.030 0.028
H9 ACGGCGCTTCTATCGGATCtgcGGCGCaATgTCGGGA ɛ3 0.029 0.030
H10 ACGGCGCTTCTATCGGATCCATGaCGCGATCTCGGaA ɛ3 0.026 0.028
H11 gtaagaacgCTATCGGATCtgcGGCGCaATgTCGGGA ɛ3 0.025 0.021
H12 gtaagaacgCCActGGATCCATGGtGCGATgcCttGg ɛ4 0.024 0.041
H13 gtGGCGCTTCTATCGGATCtgcGGCGCaATgTCGGGA ɛ3 0.018 0.017
H14 ACGGCGCcgCTActGaATCtgcGGCGCaAcgTtGtGA ɛ2 0.016 0.007
H15 ACGGCGCTTtTgTCGGATCCATGaCGCGATCTCGGaA ɛ3 0.014 0.012
H16 ACGGCGCTTtCActGGATCCATGGtGCGATCTCGGaA ɛ3 0.010 0.013
H17 ACGGCGCcgCTActGaATCtgcGGCGCaATCTCGGaA ɛ3 0.010 0.007
H18 ACGGCGCcgCTATCGGATCtgcGGCGCaATgTCGGGA ɛ3 0.010 0.014
Others 0.211 0.164
Sum 1.000 1.000
a Major andminor alleles are indicated in upper and lower case letters, respectively. The SN
and rs7412 (C/t), are indicated in bold.
b 10,000 iterations.Discussion
Here we carried out a case-control association study using high-
density SNPs to discover a disease susceptibility gene(s) for LOAD in
and around the APOE in Japanese. It was found that 36 SNPs are
strongly associated with LOAD (Fig. 1 and Table 2). These SNPs, which
were in strong LD (Fig. 3), are located in a genomic region
encompassing four genes, PVRL2, TOMM40, APOE and APOC1. Recom-
bination rate estimation revealed that the associated region is ﬁrmly
sandwiched between two recombination hotspots, HS1 and HS2
(Fig. 1B). These data raise the possibility that all four genes could be
genetically promising candidates for a predisposition to LOAD.
Further biological studies will be helpful to determine which genes
are actually involved in the LOADpathogenesis. To our knowledge, there
has only been one paper concerning the genetic association of PVRL2
with LOAD, i.e. that of Martin et al. [14]. Expression of PVRL2 has been
detected inmany organs [15] including brain (http://genecards.ccbb.re.
kr/cgi-bin/carddisp.pl?gene=PVRL2) and in several neuronal cell lines
[16,17]. PVRL2 serves as an entrymediator for herpes simplex virus type
1 (HSV-1) [16,18,19], and its DNA has been detected in the brains of
elderly normal subjects and neuronal disease patients including ones
with AD [20,21]. HSV-1 is present in a high proportion of AD brainswith
the APOE-ɛ4 allele in comparison with in non-AD ones [22]. Although
there is no direct evidence that PVRL2 is involved in LOAD development,
this gene seems to be an interesting candidate for LOAD in terms of
environmental pathogens such as viruses.
Through several genetic approaches, TOMM40 has been shown to
be strongly associated with LOAD in Caucasians [23–25]. TOMM40
encodes a channel protein that is essential for formation of a
component (TOM complex) of the translocase of the mitochondrial
outer membrane [26]. Recently, it was shown that TOMM40 is
colocalized with mitochondrially attached amyloid beta (Aβ) pre-
cursor protein (APP) in the brains of AD patients, especially in ones
with the APOE-ɛ3⁎4 genotype, but not in those of age-matched control
subjects: APOE genotype-dependent arrest of APP transport through
the TOM complex possibly causes a mitochondrial dysfunction,
resulting in LOAD development [27]. Thus, TOMM40 is considered to
be a candidate for the LOAD pathogenesis, which was also pointed out
by Li et al. [11].Chi-square Chi-squared Permutation OR 95% CIs
Control P-value P-valueb
0.337 10.153 0.0014 0.0352 0.75 (0.62–0.89)
0.081 0.54 0.4624 1.0000 0.89 (0.65–1.21)
0.042 41.971 9.26E-11 b1.0E−4 2.89 (2.07–4.03)
0.055 5.307 0.0212 0.3785 0.62 (0.41–0.94)
0.043 0.412 0.5212 1.0000 0.87 (0.57–1.33)
0.037 0.849 0.3569 1.0000 0.81 (0.51–1.28)
0.017 24.842 6.22E-07 b1.0E−4 3.36 (2.03–5.56)
0.035 0.789 0.3744 1.0000 0.80 (0.50–1.30)
0.031 0.052 0.8191 1.0000 0.94 (0.58–1.53)
0.027 0.023 0.8791 1.0000 1.04 (0.63–1.72)
0.032 2.73 0.0985 0.9308 0.64 (0.38–1.09)
0.013 17.826 2.42E-05 0.0005 3.21 (1.81–5.69)
0.021 0.649 0.4206 1.0000 0.78 (0.42–1.43)
0.024 9.696 0.0018 0.0457 0.30 (0.13–0.67)
0.017 1.203 0.2726 1.0000 0.67 (0.33–1.37)
0.010 0.412 0.5211 1.0000 1.29 (0.59–2.80)
0.014 2.517 0.1126 0.9561 0.50 (0.21–1.20)
0.008 1.949 0.1627 0.9935 1.76 (0.79–3.92)
0.156
1.000
P order, from left to right, follows the genomic position. The APOE SNPs, rs429358 (T/c)
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failure leads to AD [28]. Immunohistochemical staining of human
hippocampal tissues revealed that APOC1 is produced in astrocytes,
but not in neurons [29], and is colocalized with Aβ and APOE in senile
plaques [30]. APOC1 inhibits Aβ1–40 aggregation and causes Aβ1–40
oligomer-induced neuronal death [30]. A study on transgenic mice
demonstrated that APOC1 impairs learning and memory functions
[30]. Judging from these ﬁndings, APOC1 may contribute to the LOAD
etiology.
In conclusion, through a genetic association study on in and
around the APOE, we found that three additional genes, PVRL2,
TOMM40 and APOC1, exhibited signiﬁcant association with LOAD
(Table 2). By means of only genetic approaches, it is difﬁcult to
determinewhich gene is themost likely disease susceptibility gene for
LOAD in the associated region. At the present it is reasonable to
suppose that all four genes could contribute to the LOAD pathogenesis
from a functional point of view of these genes.
Materials and methods
Subjects
Blood samples were collected by the Japanese Genetic Study
Consortium for AD (JGSCAD), organized in 2000: the members are
listed in our recent publications [5,6]. All subjects were Japanese.
Probable AD cases met the criteria of the National Institute of
Neurological and Communicative Disorders, and Stroke-Alzheimer's
Disease and Related Disorders (NINCDS-ADRDA) [31]. Control subjects
had no signs of dementia and lived in an unassisted manner in the
local community. Age at onset (AAO) is here deﬁned as the age at
which the family and/or individuals ﬁrst noted cognitive problems
while working or in daily activities. The Mini-Mental State Examina-
tion (MMSE) and Clinical Dementia Rating and/or Function Assess-
ment Staging were used for evaluation of the cognitive impairment.
The basic demographics of the LOAD patients and the non-demented
control subjects are presented in Table 1. A total of 1262 subjects
comprising 547 LOAD patients (female, 71.7%) and 715 controls
(female, 54.4%), which is referred to as overall sample set All in this
paper, was used. The mean AAO±SD in LOAD patients was 73.0±6.9
(range, 60–93). The mean age at examination (AAE)±SD in control
subjects was 73.0±6.8 (range, 60–93). There was no signiﬁcant
difference between AAO in LOAD patients and AAE in control subjects
with the unpaired Student's t-test (P-value, 0.965). TheMMSE score in
LOAD patients (mean±SD, 16.9±7.7) was signiﬁcantly lower than
that in the controls (mean±SD, 27.4±2.6): unpaired Student's t-test,
P-valueb0.0001.
To construct three sub-sample sets, the subjects were stratiﬁed as
to the APOE-ɛ4 or APOE-ɛ3 carrier status: Negative-ɛ4 (LOAD, 298;
control, 590), Positive-ɛ4 (LOAD, 249; control, 125), and ɛ3⁎3 (LOAD,
279; control, 529).
The present study was approved by the Institutional Review Board
of Niigata University, and by all participating institutes. Informed
consent was obtained from all controls and appropriate proxies for
patients, and all samples were anonymously analyzed for genotyping.
Extraction and quantiﬁcation of genomic DNA
Genomic DNA was extracted from peripheral blood with a
QIAamp® DNA Blood Maxi Kit (Qiagen), and was ﬂuorometrically
quantiﬁed with Quant-iT™ PicoGreen® reagent (Invitrogen) accord-
ing to the manufacturer's protocol.
SNPs and genotyping
SNP information was obtained from four open databases: NCBI
dbSNP (Build 126; http://www.ncbi.nlm.nih.gov/SNP/), Interna-tional HapMap Project (Rel#21a/phaseII on NCBI Build 35
assembly, dbSNP Build 125; http://www.hapmap.org/index.html),
Ensemble Human (Version 45 on NCBI Build 36; http://www.
ensembl.org/Homo_sapiens/), and Celera myScience (Version R27g
on NCBI Build 35; http://myscience.appliedbiosystems.com/). From
these databases, 333 SNPs located in a 200 kb genomic region
including the APOE on chromosome 19q were initially selected in
the present study. Among them, 76 SNPs were excluded since some
did not satisfy the design criteria for the TaqMan® SNP genotyping
assay and others were not correctly positioned in the genomic
region. Finally, we used 257 SNPs for genotyping: mean inter-
marker distance±SD, 0.78±1.04 kb; 95% CIs, 0.66–0.91; range, 7–
6,099 bp (Supplementary Table 1).
SNP genotyping was conducted with an ABI PRISM 7900HT system
using TaqMan® SNP Genotyping Assays (Applied Biosystems). To
evaluate the genotyping quality of each SNP, a HWE test was
performed in 715 control subjects (see also under Statistical analysis).
Sequencing
The APOE genotypes of all subjects were determined by means of
sequencingwith a pair of primers, as described previously [5]. In order
to explore novel mutations or SNPs in and around TOMM40 and
PVRL2, all exons and their exon–intron boundaries, and the 5′
upstream regions of these genes were sequenced with 18 pairs of
primers in 48 individuals (24 LOAD patients and 24 control subjects).
The primer sequences are available on request. Each sequence analysis
was carried out by means of direct cycle sequencing with an ABI
PRISM 3100 genetic analyzer and a BigDye® Terminator v3.1 kit
(Applied Biosystems).
Statistical analysis
To determine the disease susceptibility SNPs for LOAD, the allelic
association at each of the 172 SNPs showing polymorphism and HWE
P-value≥0.01 was assessed by means of a chi-squared test based on
a 2×2 contingency table in comparison with the allele frequencies in
LOAD patients and control subjects. Bonferroni correction was
applied to correct for multiple testing (172 tests). A P-value of
0.0003 (=0.05/172) was set as the signiﬁcance threshold for the
allelic association test. OR with 95% CIs of each SNP was computed
from the 2×2 allelic contingency table as an estimate of the relative
risk for the disease. For calculation of the Punadj-allele-value and OR
with 95% CIs, the following four sample sets were used: All, Negative-
ɛ4, Positive- ɛ4 and ɛ3⁎3. For all statistical analyses mentioned above,
we used SNPAlyze software version 6.0.1 (DYNACOM, Japan; http://
www.dynacom.co.jp/).
Using the Haploview version 4.0 software (http://www.broad.mit.
edu/mpg/haploview/index.php) [32], we performed a HWE test,
calculation of pair-wise LD measures (|D′| and r-square), haplotype
estimation based on an expectation-maximization algorithm, and
case-control haplotype analysis (number of permutations, 10,000)
which involved haplotypes with frequency ≥0.01.
The statistical signiﬁcance was set at P-valueb0.05.
Recombination rate estimation
Recombination rates were calculated using software LDhat version
2.1 (http://www.stats.ox.ac.uk/~mcvean/LDhat/), which involves a
Baysian reversible-jump Markov Chain Monte Carlo (rjMCMC)
scheme under the crossing-over model [33–35]. They were averaged,
based on the results of 10-times computing for a randomly selected 96
samples from the entire sample set All. Every computation was run
with the parameters recommended in the accompanying documenta-
tion: θ=0.01 and rjMCMC=1,000,000 iterations (http://www.stats.
ox.ac.uk/~mcvean/LDhat/manual.pdf).
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